Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. ESMO 2017 Congress; abstract LBA2_PR.
Geen verhoogd risico op andere kanker bij lynchsyndroom
sep 2018 | Gynaecologische oncologie, Maag-darm-leveroncologie